Orchestra BioMed Holdings Inc. (OBIO) - Total Assets
Based on the latest financial reports, Orchestra BioMed Holdings Inc. (OBIO) holds total assets worth $100.66 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore OBIO operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Orchestra BioMed Holdings Inc. - Total Assets Trend (2020–2025)
This chart illustrates how Orchestra BioMed Holdings Inc.'s total assets have evolved over time, based on quarterly financial data. See Orchestra BioMed Holdings Inc. (OBIO) shareholders funds for net asset value and shareholders' equity analysis.
Orchestra BioMed Holdings Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Orchestra BioMed Holdings Inc.'s total assets of $100.66 Million consist of 94.0% current assets and 6.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 30.2% |
| Accounts Receivable | $95.00K | 0.1% |
| Inventory | $310.00K | 0.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Orchestra BioMed Holdings Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see OBIO company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Orchestra BioMed Holdings Inc.'s current assets represent 94.0% of total assets in 2025, a decrease from 95.2% in 2020.
- Cash Position: Cash and equivalents constituted 30.2% of total assets in 2025, down from 53.4% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is inventory at 0.3% of total assets.
Orchestra BioMed Holdings Inc. Competitors by Total Assets
Key competitors of Orchestra BioMed Holdings Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Immunitybio Inc
NASDAQ:IBRX
|
USA | $518.99 Million |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
Korea | ₩1.20 Trillion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.40 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
|
Zhejiang Shouxiangu Pharm Co
SHG:603896
|
China | CN¥3.22 Billion |
|
Jiangsu Bioperfectus Technologies Co Ltd
SHG:688399
|
China | CN¥3.65 Billion |
Orchestra BioMed Holdings Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.03 | 3.35 | 10.35 |
| Quick Ratio | 7.01 | 3.34 | 10.35 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $82.52 Million | $36.41 Million | $1.82 Million |
Orchestra BioMed Holdings Inc. - Advanced Valuation Insights
This section examines the relationship between Orchestra BioMed Holdings Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.79 |
| Latest Market Cap to Assets Ratio | 2.08 |
| Asset Growth Rate (YoY) | 50.8% |
| Total Assets | $114.86 Million |
| Market Capitalization | $238.92 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Orchestra BioMed Holdings Inc.'s assets at a significant premium (2.08x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Orchestra BioMed Holdings Inc.'s assets grew by 50.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Orchestra BioMed Holdings Inc. (2020–2025)
The table below shows the annual total assets of Orchestra BioMed Holdings Inc. from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $114.86 Million | +50.78% |
| 2024-12-31 | $76.17 Million | -20.00% |
| 2023-12-31 | $95.21 Million | -0.38% |
| 2022-12-31 | $95.57 Million | +606.53% |
| 2021-12-31 | $13.53 Million | -64.49% |
| 2020-12-31 | $38.09 Million | -- |
About Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develop… Read more